Trexquant Investment LP Has $3.97 Million Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Trexquant Investment LP trimmed its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 24.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 442,018 shares of the biotechnology company’s stock after selling 141,004 shares during the period. Trexquant Investment LP owned 0.31% of Aurinia Pharmaceuticals worth $3,969,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of AUPH. SBI Securities Co. Ltd. acquired a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at $25,000. Blue Trust Inc. raised its stake in shares of Aurinia Pharmaceuticals by 3,041.4% in the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 6,174 shares during the last quarter. FMR LLC raised its stake in shares of Aurinia Pharmaceuticals by 44.8% in the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 3,919 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Aurinia Pharmaceuticals during the fourth quarter worth approximately $96,000. Finally, Union Bancaire Privee UBP SA bought a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter valued at approximately $108,000. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Performance

Shares of NASDAQ:AUPH opened at $7.81 on Friday. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a 1-year low of $4.71 and a 1-year high of $10.67. The stock has a market capitalization of $1.07 billion, a P/E ratio of -52.06 and a beta of 1.26. The business has a 50-day moving average price of $8.10 and a two-hundred day moving average price of $8.08.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, March 27th.

Insider Buying and Selling

In related news, COO Matthew Maxwell Donley sold 65,902 shares of Aurinia Pharmaceuticals stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $527,216.00. Following the completion of the sale, the chief operating officer now directly owns 739,456 shares of the company’s stock, valued at $5,915,648. The trade was a 8.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Peter Greenleaf sold 195,593 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $1,564,744.00. Following the completion of the sale, the chief executive officer now owns 1,953,892 shares of the company’s stock, valued at $15,631,136. This represents a 9.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 343,898 shares of company stock valued at $2,753,094 over the last ninety days. Insiders own 4.30% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.